202811-08-3

Upstream product

• 1443440-70-7 N-methyl-N-phenoxyacetamide 
• 98-80-6 phenylboronic acid 
• 74-89-5 methylamine 
• 614-75-5 2-Hydroxyphenylacetic acid 

Downstream Products

• 202811-09-4 ethyl 2-(2-((N-methylcarbamoyl)methyl)phenoxy)acetate 
• 202811-10-7 2-(2-(2-(methylamino)ethyl)phenoxy)ethanol 
• 202811-12-9 (2R)-N-(2-(2-(2-hydroxyethoxy)phenyl)ethyl)-N-methyl-2-(methylamino)-3-(2-naphthyl)propionamide 
• 202811-11-8 N-((1R)-1-(N-(2-(2-(2-hydroxyethoxy)phenyl)ethyl)-N-methylcarbamoyl)-2-(2-naphthyl)ethyl)-N-methylcarbamic acid tert-butyl ester 
• 202811-24-3 N-((3E)-4-(N-((1R)-1-(N-(2-(2-(2-hydroxyethoxy)phenyl)ethyl)-N-methylcarbamoyl)-2-(2-naphthyl)ethyl)-N-methylcarbamoyl)-1,1-dimethylbut-3-enyl)-N-methylcarbamic acid tert-butyl ester 
• 202811-13-0 (3E)-4-(N-((1R)-1-(N-(2-(2-(2-Hydroxyethoxy)phenyl)ethyl)-N-methylcarbamoyl)-2-(2-naphthyl)ethyl)-N-methylcarbamoyl)-1,1-dimethylbut-3-enylcarbamic acid tert-butyl ester 
• 852951-38-3 N-methyl-2-{2-[(2S)-oxiran-2-ylmethoxy]phenyl}acetamide 

Relevant academic research and scientific papers

Base-promoted aromatic [3,3] sigmatropic rearrangement of N-acyl-O-arylhydroxylamine derivatives

The base-promoted aromatic [3,3] sigmatropic rearrangement of N-acyl-O-arylhydroxylamines giving α-(2-hydroxyphenyl)amides was successfully demonstrated. The substrates were prepared from N-substituted hydroxylamines by N-acylation followed by copper(I)-mediated O-arylation with boronic acids. Treatment of the substrates with lithium hexamethyldisilazide (LiHMDS) in THF at 0 °C to room temperature generated the corresponding amide enolates. The aromatic [3,3] rearrangement of the enolates provided the desired products in moderate to good yields. A crossover experiment produced only intramolecular products and clarified that the reaction proceeds via the aromatic [3,3] sigmatropic rearrangement, not a bond-cleavage–recombination process. Our method is a formal α-arylation of amides.

Compounds with growth hormone releasing properties

There are disclosed novel synthetic peptides of the general formula (I) Compounds of formula (I) stimulate the release of growth hormone from the pituitary in humans and animals. A method for increasing the rate and extent of growth of animals to increase their milk and wool production or for the treatment of ailments, and the use of the compounds of formula (I) for the preparation of medicaments, are also disclosed.

New highly potent dipeptidic growth hormone secretagogues with low molecular weight

Based on NN703, low molecular weight growth hormone secretagouges (GHSs) with a reduced number of hydrogen binding sites were designed by removal of the C-terminal amide group. The compounds were highly potent in combination with high efficacy in a rat pituitary cell assay, being characterized with EC50 values down to 0.8 nM. Selected compounds were tested in in vivo animal models. The oral bioavailability in dogs was 16-44%. Also, the ED50 values of the compounds were determined both in dog and swine. (C) 2000 Editions scientifiques et medicales Elsevier SAS.